Nevertheless, inhibition of PIM kinases by this drug was assessed, since it reduced 4E-BP1 phosphorylation, which is a very well established PIM kinase substrate [13], [14], [15], [21], and could be a biomarker for PIM kinase inhibition in PTCL. The gene discussed is EIF4EBP1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.